Overall five-year survival rates for angiosarcoma are about 31 percent, according to PubMed. Patients who received doxorubicin without surgery survived progression-free for about four to five-and-one-half months. Scalp angiosarcoma patients who received paclitaxel survived progression-free about seven months or about three months when the cancer was below the clavicle.
Patients with tumors having negative microscopic surgical margins and shallow depth typically survived longer, but the size of a tumor was not significant in determining the length of patients' overall survival rates, notes PubMed. Angiosarcoma is a rare, aggressive cancer that attacks the blood vessels and can develop in any part of the body.